NAVIGATIONINFORMATION REQUEST |
Michael A. Singer, M.D.
EDUCATIONAL BACKGROUND
Boston University
Boston University School of Medicine
Postgraduate Medical Training
LA County USC Medical Center, LS CA
Doheney Eye Institute, LA, CA
St.Vincent’s Hospital and Medical Center of New York
William Hagler, MD, William Jarrett, MD
SOCIETIES AND BOARDS
Ophthalmology American Academy of Ophthalmology, Fellow 1993 American Society of Retina Specialists 1994-Present Future Focus: “Transitioning to Managed Care” October 29, 1994 Expert Panel Member San Antonio Society of Ophthalmology 1996-Present
Boards Advisor for Brimonidine Retinal Detachment Study 2009 DRCRnet Protocol Writing Committee September 2009-Present ISTA Pharmaceuticals Global Advisory Board 2005-2008 Senior Posurdex Instructor for 012 (San Antonio, TX) Senior Posurdex Instructor for 016 (Bolder, CO) Senior Posurdex Instructor American Society of Retina Specialists (Palm Springs, CA) Allergan Global Advisory Board Genentech Global Advisory Board Macusight Emerald Study Advisory Board Involved with Designing Studies - 012, 016, and C032
Non-Ophthalmology Kaiser Permanente Management Association 1994-1995 Board of Directors American Diabetes Association, President July 1996-July 1998 Humana Utilization Review Board 1996-2003 Champus Utilization Review Board 1996 2003 Juvenile Diabetes Foundation, Board Member September 1999-September2002 Socrates Social Venture Fund Aspen, CO Director of Scholarship Section December 2000-2003 Board Member 2003-2007 Board Member Acumen Fund Health Technology 2001-Present Scientific Advisory Board MDTV Advisory Board 2002-Present CAMP Independence for Diabetic Children (Faculty) 1996-Present CAMP Independence (Board of Directors) 2003-2009
Other Industries Dolce Food Corporation, Founder and CEO January 2004-January 2007 Founded Ice Cream Corporation – Created a sugar free product, distributed through 1,000 supermarkets in the southern U.S. Profits donated to diabetic education and research Board Member 2007-2010
AWARDS Kaiser Permanente - Physician Innovation Award 1994 American Society of Retina Specialists Honor Award Cannes Retina Festival - Nice, France 2006 American Society of Retina Specialist 2009 Senior Honor Award - New York, NY American Society of Retina Specialist Film 2009 Festival Service Award - New York, NY
RESEARCH Principal Investigator June 2002-July 2005 A Randomized, Placebo-Controlled, Double Masked, Multi-Center, Phase III Study of the Effect of Visudyne Therapy in Occult with No Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (QLT, Inc.)
Principal Investigator (Retina) January 2003-July 2005 A Prospective, Multi-Center Clinical Trial of the Implantable Miniature Telescope (IMT) in Patients with Central Vision Impairment Associated with Age Related Macular Degeneration (VisionCare) Principal Investigator May 2003-December 2005 A Phase III, Multi-Center, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Rhufab V2 (Ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration (Genentech)
Principal Investigator August 2003-February 2006 A Phase III, Multi-Center, Randomized, Double-Masked, Active Treatment–Controlled Study of the Efficacy and Safety of Rhufab V2 (Ranibizumab) Compared to Verteporfin (Visudyne) Photodynamic Therapy in Subjects with Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration (Genetech)
Principal Investigator April 2004-September 2005 A Phase II Prospective, Randomized, Double Masked, Sham-Controlled, Dose Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients with Exudative, Subfoveal, Age-Related Macular Degeneration (Eyetech)
Principal Investigator June 2005-December 2007 A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficiency of Intravitreous Injections of 0.3, 0.03 or 0.003 µg Pegaptanib Sodium (Macugen ®), Given as Every 6 Weeks for 3 Years, to Sham Injections in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula (Eyetech)
Principal Investigator April 2004-2008 A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation of the Effect of Photodynamic Therapy Using Verteporfin (Visudyne Therapy) In Combination with Intravitreal Injection of Either 0 mg, 1 mg, or 4 mg of Triamcinolone Acetonide in Occult Subfoveal and Minimally Classic Subfoveal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (QLT, Inc.)
Principal Investigator April 2004-2008 A Six Month Phase 3, Multi-Center, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion (Allergan)
Principal Investigator January 2005-Current A 3-Year, Phase III, Multi-Center, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema (Allergan)
Principal Investigator June 2005-2008 An Open-Label, Multi-Center Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Who Have Completed the Treatment Phase of a Genentech-Sponsored Ranibizumab Study (Genentech)
Principal Investigator November 2005-2008 A Phase IIIB, Single-Masked, Multi-Center, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naive and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (Genentech)
Principal Investigator May 2006-2009 A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administrative of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration (Regeneron)
Principal Investigator October 2006-2008 A 2-year, Multi-Center, Randomized, Controlled, Masked, Dose-Finding Trial to Assess the Safety and Efficacy of Multiple Intravitreal Injections of AGN211745 in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Allergan)
Principal Investigator March 2007- 2010 A 52-Week, Masked, Multi-Center, Randomized, Controlled Trial (with Up to 13 Weeks Additional Follow-Up) to Assess the Safety and Efficacy of 700mg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (DME) (Allergan, 012)
Principal Investigator March 2007-2010 A Phase III, Multi-Center, Randomized, Sham injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion (Genentech, BRAVO)
Principal Investigator March 2007-2010 A Phase III, Multi-Center, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (Genentech, CRUISE)
Principal Investigator April 2007- Current A Randomized, Prospective, Active Controlled, Study of the Epi-Rad90 ™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration (NeoVista, Cabernet)
Principal Investigator May 2007-Current A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (Regeneron, VIEW)
Principal Investigator July 2007-2009 A 6-Month, Single-Masked, Multi-Center, Randomized, Controlled Study to Assess the Safety and Efficacy of 700mg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive therapy to Lucentis® Compared with Lucentis® Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Allergan, 016)
Principal Investigator August 2007-Current An Open-Label, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration (Regeneron)
Principal Investigator April 2007-Current A Phase III, Double-Masked, Multi-Center, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus (Genentech, Rise)
Principal Investigator May 2008-Current A Multi-Center, Masked, Randomized, Sham-controlled, Paired-Eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Brimonidine Tartrate Postior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Geographic Atrophy From Age-related Macular Degeneration (Allergan, 032 and 032D)
Principal Investigator August 2008-Current A Multi-Center, Masked, Randomized, Sham-Controlled, Parallel-Group, 6-Month (Plus 6-Month Extension) Study to Evaluate the Safety and Effects on Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Primary Open-Angle Glaucoma (Allergan, 030)
Principal Investigator 2008-2010 A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy (MacuSight, Diamond)
Principal Investigator 2008-2010 A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Eficacy of Subconjunctival Injections of Sirolimus in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy (MacuSight, Emerald)
Principal Investigator December 2007-Current A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (Regeneron, 0605)
Principal Investigator May 2008- Current Feasibility Study to Evaluate the Safety and Tolerability of the Epi-Rad90TM Ophthalmologic System for the Treatment of Subfoveal Chroidal Neoascularization (CNV) in Patients with Age-Related Macular Degeneration (AMD) That Have Failed Primary Anti-VEGF Therapy (NeoVista, Rose)
Principal Investigator April 2008-Current A Randomized, Single Masked, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap Eye in Subjects with Neovascular VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration (Regeneron, VGFT-OD-0702)
Principal Investigator 2008-Current An Open-Label, Multi-Center Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study (Genentech, Horizon)
Principal Investigator 2008-2010 A 26-Week, Open-Label Study to Assess the Safety and Efficacy of 700mg Dexamethasone Posterior Segment Drug Delivery System Applicator System in the Treatment of Vitrectomized Subjects with Diabetic Macular Edema (DME) (Allergan, 018)
Principal Investigator 2008-Current A 26 Week, Open-Label Study to Assess the Safety and Efficacy of 700mg Dexamethasone Posterior Segment Drug Delivery System Applicator System In Conjunction with Lucentisâ in the Treatment of Patients with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (Allergan, 019)
Principal Investigator 2008-Current A Randomized,Placebo Controlled, Double-Masked, Multi-Center Trial of Microplasmin Intravitreal Injection For Non-Surgical Treatment of Focal Vitreomacular Adhesion (Thrombogenics, MiviTrust)
Principal Investigator 2008-Current The Safety and Efficacy of Al-8309b Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (Alcon, Gate)
Principal Investigator 2009- Current A Phase III, Double-Masked, Multi-Center, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or On An As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (Genentech, Harbor)
Sub-Principal Investigator 2009-Current A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) (Regeneron, Copernicus)
Principal Investigator 2010-Current A Prospective Case-Crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Principal Investigator 2010-Current A 12-Month, Multi-Center, Masked Randomized, Control Study to Assess the Safety and Efficacy of 700mg Ozurdex® as Adjunctive Therapy to Lucentis ® Compared with Lucentis® Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Allergan 021)
PUBLICATIONS AND PRESENTATIONS
Singer, MA, del Cid, MR, Stelton, CR, Boord, T. Pars Plana Posterior Capsulotomy in a Patient with a Telescope Prosthesis for Age-Related Macular Degeneration. Archives of Ophthalmology (Manuscript EST05004), August 2010.
Singer, MA, Bell, DJ, Boord, T. OzurdexTM as Adjunctive Therapy to Lucentis® in Patients with Choridal Neovascularization Secondary to Age-related Macular Degeneration. 2010 American Society for Retina Specialists Conference (Abstract pending)
Kuppermann, B, Singer, MA, Tufail, A, Lou, J, Li, Xiao-Yan, Whitcup, S. OzurdexTM (Dexamethasone Intravitreal Implant) as Adjunctive Therapy to Lucentis® in Patients with Chroroidal Neovascularization Secondary to Age-Related Macular.
Singer, MA, Bell, DJ, Boyer, D. et al. Non-Steroidal Drops Safe for Long-Term Use? American Academy of Ophthalmology, poster presentation San Francisco, CA, October 2009.
Singer, MA, Bell, DJ, Boord, T. Effect of Combination Therapy with Bevacizumab and Dexamethasone Intravitreal Implant in Patients with Retinal Vein Occlusion. Vindico Medical Education, Maui, HA, December 2009.
Singer, MA, Del Cid, M., Bell, D., Trichopoulos, N, O’Conner, P, Padmanabhan, S. Unknown Case presented at the Imaging Conference at the Retina Congress as well as submitted at the film festival (2009)
Subretinal Aspiration to Repair Retinal Detachment in Retina Today October (2009)
A Patient Presenting with Castlemans Like Disease presented at Retina Congress (2009)
Singer, MA, P Wong, L Tuomi Visual Acuity after 2 Years in the Horizon Trail of PRN Intravitreal Ranibizumab (Lucentis) in Patients with Neovascular Age-related Macular Degeneration presented at the Retina Congress, New York, NY (2009)
Unknown Tumor Case presented at The Masters/Wave Meeting Maui, Hawaii (2009)
Singer, MA Benefits of Spectral Domain OCT in Refractive Eyecare June (2009)
Singer, MA, P Wong, L Tuomi Visual Acuity after 2 Years Data for Safety and Efficacy in the Horizon Trail of PRN Intravitreal Ranibizumab (Lucentis®) in Patients with Neovascular Age-related Macular Degeneration presented at the ARVO (2009) (submitted for publication)
Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for Neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 1 45:239-248.
Neovista Poster American Society of Retinal Specialist Annual Meeting Maui, Hawaii, October 11-15, 2008
Sadda 5, Shapiro H, Schneider 5, et al. Anatomic Outcomes at 2 Years in the ANCHOR Study Comparing Ranibizumab (Lucentis®) and Verteporfin Photodynamic Therapy (PDT) in Predominantly Classic Neovascular Age-Related Macular Degeneration (AMD). Presented at the Association for Research in Vision and Ophthalmology in Fort Lauderdale, Florida; May 6-10, 2007. ARVO Poster #8242. Data on file (14558) Data on File (14671) Data on file (14559) Data on file (14560)
Brown DM, The H, Blodi BA, et al. Lucentis® (ranibizumab) slows growth of CNV and CNV lesion in patients with neovascular AMD: 2-year angiographic results of the PIER study. Presented at the 25th Annual Meeting of the American Society of Retinal Specialists in Indian Wells, California; December 1-5, 2007 (ASRS Abstract)
Singer, MA, Wong, RL, Rodriguez, J, Alderete, C, Johnson, S. Like Reaction After Oral Moxifloxacin (Avelox) Administration Presented at American Society of Retina Specialist 25th Annual Meeting. Palm Springs, California, December 1-5, 2007.
Genentech Granted Six-Month Priority Review for Lucentism for the Treatment of Wet Age-Related Macular Degeneration. [press release]. South San Francisco: Genentech, Inc.; February 28, 2006. February 28, 2006, http://Jfwww.cenacomIaenelnewsIpiessreleases/dispydo?rnethoddetaiI&id=942i
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration. N EngI 3 Med 2006;355:1432-1444.
Singer, MA, Wong, RL; Alderete, C, Hartman, R. Vitrase for Vitreous Hemorrhage Revisited Presented at The Cannes Retina Festival Nice, France, September 9-13, 2006.
Singer, MA, Wong, RL, Alderete, C, Hartman, R. Avastin – It’s Not Just For Retina Anymore. Presented at the Cannes Retina Festival Nice, France; 9-13 September 2006
Singer, MA, Fisher, SJ, Hartman, R. Surgical Capsulotomy in an Implantable Miniature Telescope Patient Presented at the American Society of Retina Specialists Montreal, Quebec, Canada, July 16-20 2005.
Singer, MA, Kimbrell, PN Comparison of Central Retinal Artery Occlusion in Eyes With and Without Hyperbaric Oxygen Presented at the American Society of Retina Specialists Montreal, Quebec, Canada, July 16-20, 2005.
Heir, JS, Hudson, HL, Martin, DF, Berinstein, DM, Singerman, LJ, Leonard, RE, Connolly, BP, Kuppermann, BD, Singer, MA. Treatment of Central Vision Loss Associated with Macular Degeneration: 6-Month Results of the Implantable Miniature Telescope Phase II/III Trial Presented at the American Society of Retina Specialists San Diego, California; 16-20 August 2004.
Singer, MA. Age-Related Macular Degeneration San Antonio Medicine, Volume 56 Number 3, March 2003.
Singer, MA, Cohen, JH, Scribbick, F, Garcia, IM, Paulson, C. Increases in Intraocular Pressure after Kenalog Injection Presented at the American Society of Retina Specialists Annual Meeting New York, New York; August 2003.
Shields, C, Piccone, M, Shields, J, Eagle, R, Singer, MA. Mushroom-shaped Choridal Recurrence of Retinoblastoma-25 Years After Therapy. Archives of Ophthalmology Vol. 120, June 2002. Warman, JR, Crawford, J, Evans, RM, Simmons, JW, Stanley, EA, Strohlow, R, Singer, MA. Dependency-Induced Increase in Intraocular Pressure: A Contributing Factor for Postoperative Visual Loss After Spinal Surgery Poster Exhibit Presented at the Scoliosis Research Society Annual Meeting Seattle, Washington; September 2002.
Singer, MA. Transthermotherapy in the Treatment of Classic and Occult Choroidal Neovascularization. Presented at the IRIS Pre-Academy Meeting October 2000; 2001 Vitreous Society Meeting; and “Expert Speaker” Iridex Booth American Academy of Ophthalmology 2001.
Singer, MA, Botulinum, T. Treatment of Essential Blepharospasm and Heminfacial Spasm. Ophthalmology Vol 3, 3 pg 48, September 1996.
Singer, MA, Levy, G. The Evidence of Plaquenil Retinopathy in a Large Multi-Center Outpatient Practice. Presented at American Academy of Ophthalmology Meeting October 1995.
Singer, MA, Kowalski, G. The use of EMLA to Reduce Pain of Botulinum Toxin Injections Presented at Blepharospasm Foundation Conference, September 1995.
Singer MA, Rio, N. The Pathologic Effects of Retained Perflourocarbons Presented at the Vitreous Society August 1994.
Singer, MA, Hagler, WS, Grossniklaus, HE. Toxoplasmosa Gondii Retinochoroiditis After Liver Transplantation Retina Vol 13 (Issue No 1) pg 40-45, 1993.
Singer MA. Schwatz, SD, Green, RL, et al. Factors Associated with Retinal Detachment in Penetrating Ocular Trauma. Investigative Science; 1988 (29): 303 Presented as a poster ARVO 1988, Sarasota, Florida
Gaster, R, Burstein, N, Singer, M.A. Laser Surgery of the Cornea. Investigative Ophthalmology and Visual Sciences; 1987 (14); 45. Presented as a paper ARVO, Sarasota, Florida (1987)
Singer, M.A.; Wong, E.; Yaplee, S. The Presentation of a Lost Contact Lens, (Letter) CLAO, 1986 Oct-Dec (4) p. 200-201, presented at CLAO meeting, Las Vegas, Nevada, 1986 (poster)
LICENSURE Texas State Medical License – May 18, 1995 - Current California State Medical License – July 6, 1987 - Current Florida State Medical License – August 20, 2003 - Current Arizona State Medical License – September 17, 2003 - Current Department of Public Safety – Texas Controlled Substances Certification
|
